Nanoparticles in prevention of protein glycation

Aruna Sivaram1, Nayana Patil1

  • 1School of Bioengineering Sciences and Research, MIT ADT University, Pune, India.

Vitamins and Hormones
|July 12, 2024
PubMed

Insights

Advanced glycation end products (AGEs) contribute to disease by binding to the receptor for AGEs (RAGEs). Nanoparticles offer a promising therapeutic strategy for targeting the RAGE pathway due to their enhanced bioavailability and delivery capabilities.

Area of Science:

  • Biochemistry and Molecular Biology
  • Nanomedicine
  • Pathophysiology

Background:

  • Advanced glycation end products (AGEs) form via non-enzymatic carbohydrate attachment to macromolecules.
  • AGEs bind to the receptor for AGEs (RAGEs), a key factor in disease initiation and progression.

Purpose of the Study:

  • To explore the role of AGEs and RAGEs in disease pathogenesis.
  • To review nanoparticle-based strategies for targeting the AGE-RAGE pathway.

Main Methods:

  • Review of literature on AGEs, RAGEs, and nanoparticle applications.
  • Discussion of nanoparticle advantages in therapeutic targeting.

Main Results:

  • AGE-RAGE interactions are implicated in various disease processes.
  • Nanoparticles present significant advantages for targeting the AGE-RAGE pathway.

Conclusions:

  • Understanding the AGE-RAGE axis is crucial for developing novel therapeutic interventions.
  • Nanoparticles offer a promising platform for advanced therapeutic strategies against AGE-RAGE-mediated diseases.